$HOOK News

HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics

HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics

Trading Halt: Halt status updated at 4:30:00 PM ET: Quotation Resumption: News and Resumption Times

Trading Halt: Halt status updated at 4:30:00 PM ET: Quotation Resumption: News and Resumption Times

HOOKIPA Pharma To Voluntarily Delist And Deregister

Trading Halt: Halted at 4:01:00 p.m. ET - Trading Halt: Halt News Pending

HOOKIPA Pharma Q1 EPS $(1.23) Misses $(0.62) Estimate, Sales $2.00M Miss $3.38M Estimate

HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)

HOOKIPA Pharma's Board Has Determined That It Does Not Intend To Make An Offer For Poolbeg

Hookipa Pharma announces enrollment completion of Phase 1b HB-500 trial

HOOKIPA Pharma Announces Enrollment Completion of Phase 1b Clinical Trial Evaluating HB-500 for the Treatment of HIV

HOOKIPA Pharma Announces Enrollment Completion Of Phase 1b Clinical Trial Evaluating HB-500 For Treatment Of HIV, Primary Completion Expected H2 2025

HC Wainwright & Co. Downgrades HOOKIPA Pharma to Neutral

Poolbeg Pharma plc (“Poolbeg”) and HOOKIPA Pharma Inc. (“HOOKIPA”) Update on Potential Combination of Poolbeg and HOOKIPA

HOOKIPA Pharma Inc - FORM 8 (OPD)

HOOKIPA Pharma Announces Notice to Shareholders Regarding U.K. Disclosure Requirements

HOOKIPA Pharma Inc. (“HOOKIPA”) Rule 2.9 Announcement – Amendment

Hookipa Pharma, Poolberg Pharma in Discussions for All-Stock Merger

Poolbeg Pharma plc (“Poolbeg” or the “Company”) Combination of Poolbeg and HOOKIPA Pharma Inc.

RBC Capital Downgrades HOOKIPA Pharma to Sector Perform, Lowers Price Target to $2